Translational Advances in Oncogene and Tumor-Suppressor Gene Research
Cancers,
Год журнала:
2025,
Номер
17(6), С. 1008 - 1008
Опубликована: Март 17, 2025
Cancer,
characterized
by
the
uncontrolled
proliferation
of
cells,
is
one
leading
causes
death
globally,
with
approximately
in
five
people
developing
disease
their
lifetime.
While
many
driver
genes
were
identified
decades
ago,
and
most
cancers
can
be
classified
based
on
morphology
progression,
there
still
a
significant
gap
knowledge
about
genetic
aberrations
nuclear
DNA
damage.
The
study
two
critical
groups
genes—tumor
suppressors,
which
inhibit
promote
apoptosis,
oncogenes,
regulate
survival—can
help
to
understand
genomic
behind
tumorigenesis,
more
personalized
approaches
diagnosis
treatment.
Aberration
tumor
undergo
two-hit
loss-of-function
mutations,
activated
forms
proto-oncogenes
that
experience
one-hit
gain-of-function
are
responsible
for
dysregulation
key
signaling
pathways
cell
division,
such
as
p53,
Rb,
Ras/Raf/ERK/MAPK,
PI3K/AKT,
Wnt/β-catenin.
Modern
breakthroughs
genomics
research,
like
next-generation
sequencing,
have
provided
efficient
strategies
mapping
unique
changes
contribute
heterogeneity.
Novel
therapeutic
enabled
medicine,
helping
address
variability
suppressors
oncogenes.
This
comprehensive
review
examines
molecular
mechanisms
tumor-suppressor
they
regulate,
epigenetic
modifications,
heterogeneity,
drug
resistance
drive
carcinogenesis.
Moreover,
explores
clinical
application
sequencing
techniques,
multiomics,
diagnostic
procedures,
pharmacogenomics,
treatment
prevention
options,
discussing
future
directions
emerging
technologies.
Язык: Английский
Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives
Journal of Enzyme Inhibition and Medicinal Chemistry,
Год журнала:
2025,
Номер
40(1)
Опубликована: Апрель 2, 2025
Steroidal
compounds
have
emerged
as
effective
therapeutic
agents
in
oncology.
Beyond
natural-occurring
and
synthetic
steroids
that
act
cytotoxic
anti-tumoral
agents,
steroidal
derivatives
can
be
designed
to
mime
the
endogenous
substrates
of
key
metabolic
enzymes
steroidogenesis,
thus
reducing
circulating
levels
relevant
oestrogenic
androgenic
hormones
responsible
for
cancer
survival
proliferation.
Therefore,
enzyme
inhibition
represents
an
intriguing
endocrine
approach
treatment
hormone-dependent
tumours,
such
breast
prostate
cancer,
with
well-known
approved
drugs
several
pre-clinical
clinical
candidates
under
investigation.
This
review
summarises
advancements
over
past
decade
(2014-2024)
development
inhibitors
endowed
anticancer
activity,
illustrating
their
mechanisms
action,
potential,
drug
design
approaches,
current
applications.
Furthermore,
we
discuss
challenges
related
resistance,
off-target
effects,
future
strategies
optimise
efficacy
Язык: Английский
Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review
journal of nutritional oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 11, 2025
Intermittent
fasting
(IF)
has
emerged
as
a
potential
adjunctive
strategy
in
cancer
prevention,
mitigation,
and
treatment.
This
narrative
review
synthesizes
existing
literature
to
explore
the
relationship
between
IF
across
3
dimensions:
We
examine
underlying
mechanisms
by
which
may
reduce
risk,
including
its
effects
on
insulin-like
growth
factor
1
suppression,
autophagy
induction,
chronic
inflammation
reduction.
Furthermore,
we
discuss
IF’s
enhance
efficacy
of
conventional
therapies
sensitizing
cells,
promoting
apoptosis,
reducing
treatment-related
side
effects.
While
promising,
evidence
is
still
limited,
further
research
required
elucidate
long-term
impact
optimal
implementation
care.
aims
provide
health
care
professionals
patients
with
comprehensive
understanding
benefits
risks
associated
complementary
approach
oncology
setting.
Язык: Английский